Comparing seroprevalence and antibody kinetics in three different commercially available assays for SARS-CoV-2. Serostatus of COVID-19 patients was analyzed 5 months and 10 months after their infection, using three different assays: Diasorin LIAISON, Euroimmun, Abbott Diagnostics ARCHITECT. Seropositivity at baseline differed significantly depending on the assay (Diasorin 81%, Euroimmun 83%, Abbott 59%). At follow-up antibody levels detected in the Diasorin assay were stable, while there was a significant loss in seropositivity in the Euroimmun and Abbott assays. There are significant differences in SARS-CoV-2 antibody kinetics based on the specific assay used.
All Keywords
【저자키워드】 Medical research, Molecular medicine, 【초록키워드】 SARS-CoV-2, antibody, Seroprevalence, Infection, SARS-CoV-2 antibody, antibody kinetics, Seropositivity, Follow-up, Euroimmun, COVID-19 patient, LIAISON, Abbott, significant difference, significant differences, DiaSorin, Abbott Diagnostics, analyzed, significantly, assays, baseline, 【제목키워드】 SARS-CoV-2, Kinetics,
【저자키워드】 Medical research, Molecular medicine, 【초록키워드】 SARS-CoV-2, antibody, Seroprevalence, Infection, SARS-CoV-2 antibody, antibody kinetics, Seropositivity, Follow-up, Euroimmun, COVID-19 patient, LIAISON, Abbott, significant difference, significant differences, DiaSorin, Abbott Diagnostics, analyzed, significantly, assays, baseline, 【제목키워드】 SARS-CoV-2, Kinetics,
SARS-CoV-2에 대해 상업적으로 이용 가능한 세 가지 분석에서 혈청유병률 및 항체 동역학 비교. COVID-19 환자의 혈청 상태는 감염 후 5개월 및 10개월 후 Diasorin LIAISON, Euroimmun, Abbott Diagnostics ARCHITECT의 세 가지 분석을 사용하여 분석되었습니다. 기준선에서 혈청 양성은 분석에 따라 크게 달랐습니다(Diasorin 81%, Euroimmun 83%, Abbott 59%). 추적 조사에서 Diasorin 분석에서 검출된 항체 수준은 안정적이었지만 Euroimmun 및 Abbott 분석에서는 혈청 양성에 상당한 손실이 있었습니다. 사용된 특정 분석에 따라 SARS-CoV-2 항체 동역학에 상당한 차이가 있습니다.